Meyka Pro banner
Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (ORKA) Stock Overview

Explore Oruka Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ORKANASDAQ
HealthcareBiotechnology
$107.96
$3.10(2.96%)
U.S. Market opens in NaNh NaNm

Oruka Therapeutics, Inc. (ORKA)

Meyka AI Score

Z

Key Financials

Market Cap6.5B
P/E Ratio-43.68
EPS (TTM)$-1.94
ROE-0.21%
Fundamental Analysis

AI Price Forecasts

1 Month$101.41
3 Months$74.67
1 Year Target$34.82

ORKA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Oruka Therapeutics, Inc. (NASDAQ: ORKA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Oruka Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ORKA on the NASDAQ shows an RSI of 62.11, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $34.82 for the NASDAQ listing.

Key metrics behind Oruka Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -43.68 and a market capitalization of 6.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ORKA on the NASDAQ.

Price Performance (NASDAQ: ORKA)

1-Day Change
2.96%
5-Day Change
1.83%
1-Month Change
14.46%
3-Month Change
83.95%
6-Month Change
233.83%
Year-to-Date (YTD) Change
256.19%
1-Year Change
629.95%
3-Year Change
338.86%
5-Year Change
204.97%
All-Time (Max) Change
-100.00%

Contact Information

203-554-7604
855 Oak Grove Avenue, Menlo Park, CA, 94025

Company Facts

680 Employees
IPO DateAug 8, 1997
CountryUS
Actively Trading

Frequently Asked Questions